An update on therapeutic drug monitoring for antiretroviral drugs.
There is an increasing uptake of TDM of antiretroviral drugs, particularly in Europe. There is consensus that current antiretroviral drugs meet most of the criteria of drugs that can be considered as candidates for a TDM strategy. This review examines the pharmacokinetic-pharmacodynamic relationship for protease inibitors and non nucleoside reverse transcriptase inhibitor, give an overview of the published randomised clinical trials and then summarises the scenarios for use of TDM. Finally the development of the inhibitory quotient (IQ) concept is discussed.
Back
David
D
Pharmacology Research Laboratories, University of Liverpool, 70 Pembroke Street, Liverpool, USA. daveback@liverpool.ac.uk
Gibbons
Sara
S
Khoo
Saye
S
D016903:Drug Monitoring / Q000706:statistics & numerical data*; D006801:Humans; D011480:Protease Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology*; D016032:Randomized Controlled Trials as Topic; D018894:Reverse Transcriptase Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology*
D011480:Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors